The FDA recently convened an expert panel which debated whether there should be stronger warnings about potential adverse effects of Selective Serotonin Reuptake Inhibitors (SSRI) use during pregnancy. This comes after much previous debate around the current antidepressant black box warning related to increased suicidal thoughts and behaviors in young people aged 24 and younger. In observing these debates, it’s easy to see two things that are overlooked – first, that medical interventions should be assessed at an individual patient level. Secondly, we also ignore a much bigger issue – the woeful inadequacy of access to treatment in general.
Debating SSRIs While Millions with Mental Health Conditions Go Untreated
